Inmune Bio Statistics
Want to see INMB full AI Analyst Report?
Inmune Bio (INMB) Stock Statistics & Valuation Metrics
Total Valuation
Inmune Bio has a market cap or net worth of $34.98M. The enterprise value is $39.11M.
- Market Cap
- $34.98M
- Enterprise Value
- $39.11M
Share Statistics
Inmune Bio has 30,959,080 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 30,959,080
- Owned by Insiders
- 9.69%
- Owned by Institutions
- 6.29%
Financial Efficiency
Inmune Bio’s return on equity (ROE) is -1.95 and return on invested capital (ROIC) is -125.70%.
- Return on Equity (ROE)
- -1.95
- Return on Assets (ROA)
- -1.42
- Return on Invested Capital (ROIC)
- -125.70%
- Return on Capital Employed (ROCE)
- -1.29
- Revenue Per Employee
- 2,380.952
- Profits Per Employee
- -2.19M
- Employee Count
- 21
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Inmune Bio is -1.77. Inmune Bio’s PEG ratio is -0.02.
- PE Ratio
- -1.77
- PS Ratio
- 0.00
- PB Ratio
- 1.69
- Price to FCF
- -2.50
- Price to Operating Cash Flow
- -2.37
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, Inmune Bio had revenue of 50.00K and earned -45.93M in profits. Earnings per share was -1.86.
- Revenue
- 50.00K
- Gross Profit
- 50.00K
- Operating Income
- -30.87M
- Pretax Income
- -45.93M
- Net Income
- -45.93M
- EBITDA
- -45.85M
- Earnings Per Share (EPS)
- -1.86
Cash Flow
In the last 12 months, operating cash flow was -12.92M and capital expenditures -705,999, giving a free cash flow of -14.06M billion.
- Operating Cash Flow
- -12.92M
- Free Cash Flow
- -14.06M
- Free Cash Flow per Share
- -0.49
Dividends & Yields
Inmune Bio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -46.05%
- Earnings Yield
- -54.48%
Stock Price Statistics
- Beta
- 1.59
- 52-Week Price Change
- -30.67%
- 50-Day Moving Average
- 1.88
- 200-Day Moving Average
- 1.63
- Relative Strength Index (RSI)
- 24.28
- Average Volume (3m)
- 321.22K
Important Dates
Inmune Bio upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Inmune Bio as a current ratio of 3.55, with Debt / Equity ratio of 4.40%
- Current Ratio
- 3.55
- Quick Ratio
- 3.55
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.52
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Inmune Bio has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Inmune Bio EV to EBITDA ratio is -0.92, with an EV/FCF ratio of -1.10.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.92
- EV to Free Cash Flow
- -1.10
- EV to Operating Cash Flow
- -1.19
Balance Sheet
Inmune Bio has $16.33M in cash and marketable securities with $1.21M in debt, giving a net cash position of $15.12M billion.
- Cash & Marketable Securities
- $16.33M
- Total Debt
- $1.21M
- Net Cash
- $15.12M
- Net Cash Per Share
- $0.49
- Tangible Book Value Per Share
- $0.65
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Inmune Bio is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- 71.08%
Scores
- Smart Score
- 4
- AI Score
- 51
